Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STR-0002
- Development stage
- Preclinical
- Lead developer
- SATOR Therapeutics
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intravenous
01
Overview
STR-0002 is a non-engineered, non-pathogenic, naturally occurring human oncolytic virus being developed by SATOR Therapeutics. It is designed to selectively infect and lyse cancer cells while simultaneously stimulating a systemic anti-tumor immune response. Part of a broader library of oncolytic viruses, STR-0002 is intended for systemic administration via intravenous infusion. It is currently being advanced for the treatment of mesothelioma and glioblastoma multiforme (GBM), with the goal of potentially being used in combination with other viruses to enhance efficacy and mitigate the impact of neutralizing antibodies.
Beyond the preview
Go deeper on STR-0002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STR-0002.